• Bolt Biotherapeutics posted a net loss of $7.24 million, narrowing from $11.04 million a year earlier; loss from operations improved to $7.6 million from $12.1 million.
• Revenue slid to $26,000 from $1.22 million, while R&D expense fell to $4.83 million from $9.51 million.
• G&A expense dropped to $2.8 million from $3.83 million; cash, cash equivalents, and marketable securities totaled $23.9 million as of March 31, expected to fund operations into 2027.
• Phase 1/2 study of claudin 18.2-targeted BDC-4182 continued enrolling gastric and gastroesophageal cancer patients, with initial clinical data expected in 3Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bolt Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121605PRIMZONEFULLFEED9717894) on May 12, 2026, and is solely responsible for the information contained therein.